Skip to main content
Delta-Fly Pharma, Inc. logo

Delta-Fly Pharma, Inc. — Investor Relations & Filings

Ticker · 4598 ISIN · JP3549370009 T Professional, scientific and technical activities
Open in API
Filings indexed 63 across all filing types
Latest filing 2026-05-11 Regulatory Filings
Country JP Japan
Listing T 4598

About Delta-Fly Pharma, Inc.

https://www.delta-flypharma.co.jp/en/

Delta-Fly Pharma, Inc. is a biopharmaceutical company specializing in the research and development of anticancer drugs. The company's core strategy is its proprietary "Module Drug Development" concept, an approach that combines existing pharmaceutical components to create novel therapeutic agents. This methodology aims to develop effective cancer treatments with significantly reduced side effects and at reasonable prices, thereby improving the quality of life for patients. The company's pipeline includes several drug candidates for various cancers, with some, such as DFP-10917 for refractory/relapsed acute myeloid leukemia, advancing to late-stage clinical trials. Delta-Fly Pharma focuses on creating gentle yet potent therapies, including nucleoside analogs and RNA therapeutics.

Recent filings

Filing Released Lang Actions
DFP-10917の商標の国際登録とNDA承認取得の見通しに関するお知らせ
Regulatory Filings Classification · 85% confidence The document is a corporate announcement (“お知らせ”) regarding the international trademark registration of DFP-10917 trademarks and the outlook for NDA approval discussions with the FDA. It provides operational and regulatory updates rather than financial statements, meeting materials, or insider transactions. It does not fit into any specific category like earnings releases, capital changes, or M&A, so it falls under the generic Regulatory Filings category.
2026-05-11 Japanese
第11回新株予約権（行使価額修正条項付新株予約権）の 月間行使状況に関するお知らせ
Regulatory Filings
2026-05-01 Japanese
第11回新株予約権（行使価額修正条項付新株予約権）の 大量行使に関するお知らせ
Regulatory Filings
2026-04-17 Japanese
DFP-10917単剤及びVEN併用の米国ＦＤＡとの協議準備に関するお知らせ
Regulatory Filings
2026-04-16 Japanese
DFP-17729の臨床第2/3相比較試験の進捗状況に関するお知らせ
Regulatory Filings
2026-04-15 Japanese
有価証券届出書（組込方式）
Regulatory Filings Classification · 97% confidence The document is a '有価証券届出書' (Securities Registration Statement) filed with the Kanto Local Finance Bureau by Delta-Fly Pharma, Inc. It details the issuance of new share acquisition rights (第11回新株予約権). This type of document is a formal regulatory filing required for capital raising activities in Japan. Since it is a primary registration document for a securities offering rather than a simple announcement or a periodic financial report, it falls under the 'Regulatory Filings' category as the most appropriate classification for this specific type of Japanese financial disclosure.
2026-01-16 Japanese

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.